vs
Side-by-side financial comparison of Cambium Networks Corp (CMBM) and FIBROGEN INC (KYNB). Click either name above to swap in a different company.
Cambium Networks Corp is the larger business by last-quarter revenue ($40.3M vs $25.4M, roughly 1.6× FIBROGEN INC). Cambium Networks Corp runs the higher net margin — -17.9% vs -129.8%, a 111.9% gap on every dollar of revenue. On growth, Cambium Networks Corp posted the faster year-over-year revenue change (-23.2% vs -29.9%). Cambium Networks Corp produced more free cash flow last quarter ($-10.8M vs $-59.3M). Over the past eight quarters, FIBROGEN INC's revenue compounded faster (-7.8% CAGR vs -27.2%).
Cambium Networks Corporation is an American manufacturer of wireless telecommunications equipment, including Enterprise WiFi, Network switch, Internet of Things, and fixed wireless broadband and Wi-Fi for enterprises products for Internet access. Publicly traded on the NASDAQ stock exchange, it spun out of Motorola in October 2011.
FibroGen Inc. is a biopharmaceutical firm developing and commercializing innovative therapies for unmet medical needs, targeting fibrotic diseases, anemia and cancer. Its lead product roxadustat is approved in multiple markets including China and Japan, serving patients across key therapeutic segments.
CMBM vs KYNB — Head-to-Head
Income Statement — Q4 FY2024 vs Q1 FY2024
| Metric | | |
|---|---|---|
| Revenue | $40.3M | $25.4M |
| Net Profit | $-7.2M | $-32.9M |
| Gross Margin | 36.6% | 15.9% |
| Operating Margin | -28.4% | -193.9% |
| Net Margin | -17.9% | -129.8% |
| Revenue YoY | -23.2% | -29.9% |
| Net Profit YoY | 71.0% | 57.1% |
| EPS (diluted) | $-0.26 | $-0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 24 | $40.3M | — | ||
| Q3 24 | $44.7M | — | ||
| Q2 24 | $45.2M | — | ||
| Q1 24 | $47.1M | $25.4M | ||
| Q4 23 | $52.5M | $-73.8M | ||
| Q3 23 | $44.6M | $40.1M | ||
| Q2 23 | $53.7M | $44.3M | ||
| Q1 23 | $76.0M | $36.2M |
| Q4 24 | $-7.2M | — | ||
| Q3 24 | $-34.5M | — | ||
| Q2 24 | $-14.2M | — | ||
| Q1 24 | $-18.4M | $-32.9M | ||
| Q4 23 | $-24.9M | $-56.2M | ||
| Q3 23 | $-36.4M | $-63.6M | ||
| Q2 23 | $-13.4M | $-87.7M | ||
| Q1 23 | $671.0K | $-76.7M |
| Q4 24 | 36.6% | — | ||
| Q3 24 | 43.6% | — | ||
| Q2 24 | 32.5% | — | ||
| Q1 24 | 29.8% | 15.9% | ||
| Q4 23 | 15.2% | — | ||
| Q3 23 | 26.7% | 89.4% | ||
| Q2 23 | 39.0% | 87.1% | ||
| Q1 23 | 47.4% | 90.3% |
| Q4 24 | -28.4% | — | ||
| Q3 24 | -69.6% | — | ||
| Q2 24 | -27.2% | — | ||
| Q1 24 | -33.1% | -193.9% | ||
| Q4 23 | -44.5% | 128.8% | ||
| Q3 23 | -46.2% | -158.2% | ||
| Q2 23 | -20.9% | -198.7% | ||
| Q1 23 | 1.9% | -210.4% |
| Q4 24 | -17.9% | — | ||
| Q3 24 | -77.3% | — | ||
| Q2 24 | -31.5% | — | ||
| Q1 24 | -39.2% | -129.8% | ||
| Q4 23 | -47.5% | 76.2% | ||
| Q3 23 | -81.5% | -158.5% | ||
| Q2 23 | -25.0% | -197.8% | ||
| Q1 23 | 0.9% | -212.1% |
| Q4 24 | $-0.26 | — | ||
| Q3 24 | $-1.22 | — | ||
| Q2 24 | $-0.51 | — | ||
| Q1 24 | $-0.66 | $-0.33 | ||
| Q4 23 | $-0.90 | $-0.56 | ||
| Q3 23 | $-1.32 | $-0.65 | ||
| Q2 23 | $-0.49 | $-0.90 | ||
| Q1 23 | $0.02 | $-0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $177.6M |
| Total DebtLower is stronger | $67.6M | — |
| Stockholders' EquityBook value | $-3.2M | $-228.1M |
| Total Assets | $173.7M | $365.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $177.6M | ||
| Q4 23 | — | $203.5M | ||
| Q3 23 | — | $251.3M | ||
| Q2 23 | — | $335.7M | ||
| Q1 23 | — | $355.9M |
| Q4 24 | $67.6M | — | ||
| Q3 24 | $67.6M | — | ||
| Q2 24 | $68.9M | — | ||
| Q1 24 | $63.8M | — | ||
| Q4 23 | $25.1M | — | ||
| Q3 23 | $25.8M | — | ||
| Q2 23 | $26.4M | — | ||
| Q1 23 | $27.0M | — |
| Q4 24 | $-3.2M | — | ||
| Q3 24 | $1.9M | — | ||
| Q2 24 | $34.1M | — | ||
| Q1 24 | $45.0M | $-228.1M | ||
| Q4 23 | $61.1M | $-204.2M | ||
| Q3 23 | $82.5M | $-157.2M | ||
| Q2 23 | $116.5M | $-102.3M | ||
| Q1 23 | $125.8M | $-48.9M |
| Q4 24 | $173.7M | — | ||
| Q3 24 | $194.3M | — | ||
| Q2 24 | $221.1M | — | ||
| Q1 24 | $219.8M | $365.9M | ||
| Q4 23 | $209.1M | $423.5M | ||
| Q3 23 | $222.4M | $460.4M | ||
| Q2 23 | $275.7M | $515.1M | ||
| Q1 23 | $280.4M | $538.5M |
| Q4 24 | — | — | ||
| Q3 24 | 36.12× | — | ||
| Q2 24 | 2.02× | — | ||
| Q1 24 | 1.42× | — | ||
| Q4 23 | 0.41× | — | ||
| Q3 23 | 0.31× | — | ||
| Q2 23 | 0.23× | — | ||
| Q1 23 | 0.21× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.4M | $-59.3M |
| Free Cash FlowOCF − Capex | $-10.8M | $-59.3M |
| FCF MarginFCF / Revenue | -26.8% | -233.9% |
| Capex IntensityCapex / Revenue | 1.1% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-21.4M | $-274.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 24 | $-10.4M | — | ||
| Q3 24 | $8.9M | — | ||
| Q2 24 | $2.4M | — | ||
| Q1 24 | $-15.9M | $-59.3M | ||
| Q4 23 | $-5.8M | $-18.3M | ||
| Q3 23 | $-345.0K | $-84.5M | ||
| Q2 23 | $-4.5M | $-110.6M | ||
| Q1 23 | $-6.1M | $-101.6M |
| Q4 24 | $-10.8M | — | ||
| Q3 24 | $6.8M | — | ||
| Q2 24 | $87.0K | — | ||
| Q1 24 | $-17.4M | $-59.3M | ||
| Q4 23 | $-7.4M | $-18.6M | ||
| Q3 23 | $-1.5M | $-85.2M | ||
| Q2 23 | $-5.2M | $-111.6M | ||
| Q1 23 | $-7.5M | $-102.2M |
| Q4 24 | -26.8% | — | ||
| Q3 24 | 15.2% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | -37.0% | -233.9% | ||
| Q4 23 | -14.0% | 25.2% | ||
| Q3 23 | -3.3% | -212.3% | ||
| Q2 23 | -9.7% | -251.7% | ||
| Q1 23 | -9.9% | -282.6% |
| Q4 24 | 1.1% | — | ||
| Q3 24 | 4.8% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 3.3% | 0.1% | ||
| Q4 23 | 3.1% | -0.3% | ||
| Q3 23 | 2.5% | 1.7% | ||
| Q2 23 | 1.2% | 2.2% | ||
| Q1 23 | 1.9% | 1.6% |
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | -9.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMBM
| Enterprise | $16.6M | 41% |
| Point To Multi Point | $16.4M | 41% |
| Other | $5.8M | 14% |
KYNB
| Drug Product Revenue | $24.5M | 97% |
| Other | $878.0K | 3% |
